By Margaretta Colangelo, Managing Partner at Deep Knowledge Ventures. View original article here.
Today Deep Knowledge Analytics published AI-Friendly CEOs and Board Members in Pharma and Tech Corporations. This special report is based on comprehensive research on 50 pharma and tech corporations that are applying AI in advanced biomedicine. This open access report identifies 100 CEOs and board members who are driving the implementation of AI in biomedicine and supporting the growth of AI globally. The presence of AI-friendly CEOs and board members is an indication that a company is focused on increasing R&D efficiency and thus is more likely to succeed in the drug discovery and advanced healthcare sectors. The objective of this report is to establish a benchmark. In the future we expect to observe a correlation between such benchmarking and market and investment prospects with the level of AI commitment serving as an indicator of market capitalization growth.